Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2464

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2464
---
 (1) a malaria vaccine candidate against PfSEA-1
and/or against PfGARP; (2) a humanized mAb malaria product candidate against PfGARP; and (3) a small molecule malaria product candidate,
also against PfGARP.

Importantly,
Dr. Kurtis’ antigen discoveries described above were enabled by his development of our Whole Proteome Differential Screening target
discovery platform (the “WPDS” platform). We believe the WPDS platform may enable us to discover new targets for other infectious
diseases in the future. The WPDS platform leverages the fact that the immune system, when exposed to an infectious disease such as malaria,
will often naturally produce a wide array of antibodies to try fighting the infection. Only a small subset of these antibodies may prove
effective, and the WPDS platform is designed to identify these antibodies and their corresponding antigens. We believe that such antibodies
and antigens could inform the development of therapeutic and/or vaccine candidates against the particular infectious disease. Prior to
in-licensing our product candidates, the preclinical developments of the oncology, fibrosis and malaria programs described above have,
to date, been funded through grants to our licensors totaling $105.6 million.

10

The
table below summarizes our product candidate pipeline, target indications, estimated addressable patient populations, and stage of development.

Our
Team

Our
scientific co-founders and members of our board of directors are Dr. Elias and Dr. Kurtis. Our executive chairman and co-founder is Chirinjeev
Kathuria, M.D., an investor and entrepreneur who has co-founded and driven the initial public offerings, or IPOs, of companies in various
industries including healthcare Our team brings expertise in science, medicine, agile drug development,
pharma strategy, and innovation management. Collectively, members of the team have evaluated more than 3,500 innovations; been involved
in more than 80 drug discovery / development programs, 17 clinical development programs, and 8 approved drugs; have secured more than
$120 million in venture capital funding; and have been involved in the launch of 8 biotech or life sciences companies and 3 IPOs. In
addition, beyond our day-to-day leadership team, our scientific co-founders and members of our scientific advisory board and board of
directors, Dr. Elias and Dr. Kurtis, have authored or co-authored more than 350 papers, secured more than $110 million in